Loading...
Market
Which age group will have the highest uptake of FluMist nasal spray by end of 2024?
2
Resolution / Starting Odds
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
50+ years • 25%
Sales and demographic reports from AstraZeneca or major pharmacy chains
Story
FDA Approves First Self-Administered FluMist Nasal Spray for At-Home Use
Sep 20, 2024, 08:03 PM
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self- or caregiver-administration. This approval marks the first time a flu vaccine can be administered at home without the need for a healthcare provider. FluMist is licensed for individuals between the ages of 2 and 49 and is designed to prevent influenza caused by virus subtypes A and B. The vaccine, which contains a weakened live virus, will be available through third-party pharmacies, where individuals will complete a screening and eligibility assessment when ordering. This move is part of a broader effort by the FDA to expand consumer access to medicines and reduce costs and barriers to care.
View original story
Similar markets
2-12 years • 25%
13-24 years • 25%
25-34 years • 25%
35-49 years • 25%
2-12 years • 25%
13-24 years • 25%
25-35 years • 25%
36-49 years • 25%
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
Evenly distributed • 25%
2-12 years • 25%
13-29 years • 25%
30-49 years • 25%
Equal uptake across all age groups • 25%
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
Evenly distributed • 25%
2-18 years • 25%
19-29 years • 25%
30-49 years • 25%
All age groups equally • 25%
2-12 years • 25%
13-24 years • 25%
25-34 years • 25%
35-49 years • 25%
Children (6 months to 11 years) • 25%
Adolescents (12 to 17 years) • 25%
Adults (18 to 64 years) • 25%
Seniors (65 years and older) • 25%
18-24 • 25%
25-34 • 25%
35-44 • 25%
45+ • 25%
Yes • 50%
No • 50%
Less than 5% • 25%
5-10% • 25%
10-20% • 25%
More than 20% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%